Analysis on the antibody level ofepidemic cerebrospinal meningitis among healthy population in Kaifeng City from 2019 to 2020

LU Han, XIAO Meng-ying, HU Huai-jie, LU Wei-feng

Anhui Journal of Preventive Medicine ›› 2022, Vol. 28 ›› Issue (1) : 13-16.

PDF(862 KB)
PDF(862 KB)
Anhui Journal of Preventive Medicine ›› 2022, Vol. 28 ›› Issue (1) : 13-16. DOI: 10.19837/j.cnki.ahyf.2022.01.003

Analysis on the antibody level ofepidemic cerebrospinal meningitis among healthy population in Kaifeng City from 2019 to 2020

  • LU Han*, XIAO Meng-ying, HU Huai-jie, LU Wei-feng
Author information +
History +

Abstract

Objective To investigate the level of IgG antibody in serogroup A and C of epidemic cerebrospinal meningitis among healthy population in Kaifeng City,and to provide theoretical basis for prevention and control of epidemic cerebrospinal meningitis. Methods A total of 1003 subjects in 7 age groups,including <1 year,1-2 years,3-4 years,5-6 years,7-14 years,15-19 years and ≥ 20 years in Luowang Township and Dalizhuang Township of Kaifeng City from 2019 to 2020 were selected as study subjects using a random stratified sampling method.Enzyme-linked immunosorbent assay was used to detect the IgG antibody levels in serogroupp A and serogroup C of epidemic cerebrospinal meningitisserum. Results The positive rate of meningococcal serogroup A and C IgG in healthy population in Kaifeng City were 49.85% and 54.84%,respectively.The positive rate of meningococcal serogroup A (χ2=162.674,p<0.001) and C (χ2=140.422,P<0.001) were significantly different in different age groups.The positive rate of meningococcal serogroup A and C IgG antibody positivity rates were both the lowest in the <1 year old group.The IgG positive rate of serogroup A was highest in the≥20 age group.The IgG positive rate of serogroup C was highest in the 3~4 age group.Positive rate was higher in people with immunization history than in people without immunization history and people with unknown immunization history.The antibody positivity rate was higher when the vaccination period is about one year. Conclusion In Kaifeng,the serum IgG antibody levels of meningococcal serogroup A and C are relatively low in healthy population,especially in the<1 year old group.Hence,the vaccination of meningococcal vaccine should be enhanced to improve the coverage rate of meningococcal vaccine and raise the antibody level of epidemic cerebrospinal meningitis in the population.

Key words

Epidemic cerebrospinal meningitis / Antibody level / Healthy population

Cite this article

Download Citations
LU Han, XIAO Meng-ying, HU Huai-jie, LU Wei-feng. Analysis on the antibody level ofepidemic cerebrospinal meningitis among healthy population in Kaifeng City from 2019 to 2020[J]. Anhui Journal of Preventive Medicine. 2022, 28(1): 13-16 https://doi.org/10.19837/j.cnki.ahyf.2022.01.003

References

[1] 廖春艳,吴国辉,程伟,等.重庆市健康人群A 群C 群脑膜炎奈瑟菌抗体水平调查[J].中国计划免疫,2006,12(1):56-58.
[2] 李亚南,赵丹,徐颖华,等.河南省健康儿童 A、C、Y 和 W135 群流行性脑脊髓膜炎抗体水平回顾性调查[J].微生物学免疫学进展,2018,46(4):49-52.
[3] HARRISON LH,TROTTER CL,RAMSAY ME.Global epidemiology of meningococcal disease[J].Vaccine,2009,27(Suppl2):51-63.
[4] 姬艳芳,史鲁斌,杨建辉.河南省某寄宿中学流脑聚集性疫情调查处置[J].中国校医,2018,32(1):46-48.
[5] 刘倩,姬艳芳,徐瑾.2019 年河南省健康人群流脑A 群、C 群抗体水平监测[J].微生物学免疫学进展,2020,48(4):63-67.
[6] 刘振武,王晓萍,钱玉春,等.合肥市 2011 年流脑流行前期健康人群流脑带菌率及免疫水平调查[J].安徽预防医学杂志,2013,19(6):408-409,413.
[7] 谢芳钦,李曲文,罗朝晨,等.2011年福建省流脑流行期两地市健康人群带菌率及抗体水平分析[J].预防医学论坛,2016,22(4):260-262.
[8] 骆晓艳,李薇,李继南,等2014年天津市部分地区健康人群A和C群流脑抗体水平监测[J].职业与健康,2016,32(20):259-264.
[9] 闫华伟,左聪,张存良.2019 年周口市健康人群流行性脑脊髓膜炎抗体水平分析[J].深圳中西医结合杂志,2020,30(13):18-19.
[10] 中国预防医学会.脑膜炎球菌疫苗的有效性、安全性和成本效益研究进展[J].中国疫苗和免疫,2019,25(1):102-108,114.[11] 罗凤基,杨晓明,王军志,等.译.疫苗学[M].第6 版.北京:人民卫生出版社,2017:477-510.
[12] 郑佳,朱向国,刘刚,等.A 群C 群脑膜炎球菌多糖结合疫苗的免疫原性及免疫持久性观察[J].中国生物制品学杂志,2015,28(7):707-710.
[13] 赵丽娟,史丽霞,黄东升,等.2017年保山市健康人群流脑 A、C群抗体水平调查[J].预防医学论坛,2019,25(2):81-85.
[14] 王小丽,李锋,韩同武,等.2018 年郑州市农村地区健康人群流脑抗体水平调查[J].现代预防医学,2019,46(23):4380-4381,4399.
[15] 张凤,蒋丽,管庆虎,等.贵州省脑膜炎球菌多糖疫苗不同免疫策略的成本 - 效果比较分析[J].现代预防医学,2021,48(6):1043-1045,1054.
PDF(862 KB)

Accesses

Citation

Detail

Sections
Recommended

/